

Henning Gädeke
c/o Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

September 2, 2025

Letter of Endorsement - Access to Advanced Health Institute (UK)

Dear Sir/Madam,

On behalf of Access to Advanced Health (UK) or AAHI, CW Innovation Hub, 3rd Floor, Lift Bank D, Chelsea and Westminster Hospital NHS Foundation Trust, London, SW10 9NH, UK and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

AAHI is a non-profit biotech research institute that develops vaccines that are accessible to underserved communities, particularly against diseases that largely highly prevalent in low-to middle-income countries, that have a high burden of disease. We create scalable and affordable health solutions, through the development of vaccine adjuvants, that provide broad and durable immunity, temperature stable formulations and eliminate the cold chain storage and transportation. We source sustainable raw materials and endeavour to ensure cost-effective supply chains.

AAHI has an established track record in vaccine adjuvant development, advancing its tuberculosis, leishmaniasis, and leprosy vaccine candidates, through early-stage clinical trials, strategically partnering with Contract Development Manufacturing Organizations (CDMOs) that will support path to market, and supporting partner products using AAHI adjuvants as a critical ingredient in vaccines to protect against HIV, malaria, influenza, and many other disease targets.

AAHI is the sponsor and a partner in the proposal ACTTIVAC (Final ID: 101248955-2) that has been submitted to the topic HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage: Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa. AAHI will be the vaccine supplier (Work Package 3) for the proposed phase 2a clinical trial that uses the lyophilised single-vial tuberculosis vaccine candidate ID93+GLA-SE (Work Packages 4-5) and will tech transfer GMP production of its GLA-SE adjuvant formulation to Afrigen (Work Package 7).

In addition to this effort, AAHI will provide an in-kind contribution of 30 months to develop a sustainably sourced adjuvant formulation for this promising tuberculosis vaccine candidate. AAHI will perform work to replace shark-derived squalene with plant-based Solanesol in GLA-SE to prevent the culling of millions of sharks per year and at the same time create a sustainable safe vaccine. This work will include formulation development work, preclinical bridging immunogenicity and challenge studies, and a GLP toxicity study. This effort adds potential value to the achievement of the Global Health EDCTP3 JU's objective "to strengthen capacity in SSA for epidemic preparedness through effective and rapid research response to develop essential diagnostics, vaccines and therapeutics for early detection and control of emerging diseases of epidemic potential." Developing this sustainable adjuvant formulation that has increased availability, scalability, and comparable immunogenicity to the currently used GLA-SE adjuvant formulation will enable a more rapid

response to tuberculosis and work to provide sustainability in the oceans eco system.

ACTTIVAC Work Package 3 for GMP-Grade Vaccine Production, AAHI's in-kind contribution to complete Task 3.4, will include GLA-Solanesol Development, personnel costs, materials and supplies, subcontracting costs for the challenge and toxicology studies, animal facility fees, regulatory filings and manuscript preparation. We estimate the total value of this contribution to be EUR 1,940,993 as an in-kind contribution for Work Package 3.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Keeley Foley, CEO
Access to Advanced Health (UK)
CW Innovation Hub, 3rd Floor,
Lift Bank D, Chelsea and Westminster Hospital NHS Foundation Trust
London, SW10 9NH, UK
+447415313046
keeley.foley@aahi.org